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Background: International funding for global health research is not systematically documented. We have
assessed the level of research funding awarded by UK funders of international research to low- and middle-
income countries or research institutions in these countries.
Methods:Weanalysed6165 studies; fromthesewe selected522 thatmatchedourcriteriaandused themtoevalu-
ateresearchfundingbypathogen,disease, researchanddevelopmentvaluechain, fundingorganisationandcountry.
Results: Investment in infectious disease research in the countries studied totalled £264million. Distribution of re-
search investments closely mirrored that of the UK’s former colonial territories; the top five countries, and eight of
the top 10, have historical links with the UK, being current or former members of the Commonwealth of Nations.
HIV, malaria and neglected tropical diseases attracted the greatest investment (£219 million; 82.8%), with most
studies focussing on operational and epidemiological research (£109million; 41.3%).
Conclusions: International financing of infectious disease research byUK fundingorganisations follows formercolo-
nial ties. Funding institutions should review their funding policies to ensure that they also assist low- and middle-
income countries without colonial ties to address their disease burden. A global investment surveillance system is
needed to map and monitor funding for international research and guide the allocation of scarce resources to
reduce the global disease burden.
Keywords: Commonwealth, Health financing, Infectious disease, Public health policy, Research and development, Research
investments
Introduction
The burden of disease is a major barrier to development in low-
and middle-income countries.1 However, health research is dis-
proportionately concentrated in high-income countries and
devoted to illnesses that affect richer populations. In 1999, a
seminal paper by the Global Forum for Health Research documen-
ted the 10/90 gap: 10% of health research resources are devoted
to the poorest 90% of the world’s population.2 Although funding
for global health has substantially increased since 2000,3 there
remains a mismatch between burden and research financing.2
Analysis of the financing of health research is complex, as the
agencies that invest in health research use numerous organisa-
tions, channels and methods to distribute resources. A recent
study analysed the infectious disease research funding received
by UK institutions and their global partners from public and
philanthropic sources, and highlighted substantial disparities
between disease burden and funding.4
In this paper we explore the relationship between research
funding provided by UK funding agencies and the colonial links
of the recipient countries to the UK. Specifically we analyse
funding for research in countries outside the UK where invest-
ments for infectious disease research were allocated to a global
partner institution or where much of the actual research was
performed. We believe that our study is the first to systemati-
cally analyse investment outside the UK in infectious disease
research.
Methods
Wesystematically searcheddatabases andwebsites for information
on investments in infectious disease research for the period
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1997–2010. Our initial search identified 6165 studies, of which 565
were selected for analysis.We created a comprehensive database of
open-access infectious disease research projects and categorised
studies and funding by disease, cross-cutting theme (defined as
research relevant to two or more infectious diseases), and research
and development (R&D) phase.4 Full details of ourmethodologyand
search criteria, and the final database, are openly available from the
project website (http://esearchinvestments.org/data). Cross-cutting
themes included: diagnostics, vaccine and therapeutics research,
and microbiological categories such as virology, bacteriology,
parasitology and mycology. R&D categories included: preclinical
research, phase 1, 2 or 3 clinical trials, product development and
operational research. Data collected included study title, project
abstract, funding amount awarded to the study, lead institution,
principal investigator and year of award. We included all studies
for infectious diseases where the lead institution was based in the
UK and collaborated with a global partner institution, including
those in high-income settings. Veterinary infectious disease
research was excluded unless there was a clear zoonotic compo-
nent. We included open-access data from public and philanthropic
funding organisations. Projects with funding starting in the years
1997 through to 2010 were included. We excluded open-access
data from the pharmaceutical industry, as it was not accessible
for all large companies and was clearly under-representative. All
grant funding amounts were adjusted for inflation and reported
in UK£ (2010 rate) (http://www.oanda.com/currency/historical-
rates/).3 Grants awarded in a currency other than UK£ were
converted to £ using the mean exchange rate in the year of
award. Statistical analysis and generation of figures and graphs
were performed using Stata software v.11 (StataCorp, College
Station, TX, USA).
Results
In sum, £264.3 million was invested across 522 studies (see Sup-
plementary Table 1). Research investments were allocated pri-
marily to Uganda (£107.0 million; 40.5%), Zimbabwe (£76.1
million; 28.8%), South Africa (£60.0 million; 22.7%), Malawi
(£26.9 million; 10.2%), and Tanzania (£16.2 million; 6.1%)
(Figure 1). These and four other African countries accounted for
nine of the top 10 countries by total investment in the study
period. India, the only non-African country in the top 10, was at
number nine, with £12.2 million (4.6%). Research investment in
countries with no colonial links to the UK was £29.8 million
(11.3%).
HIV was the infection attracting the greatest investment
(£133.3 million; 50.4%), followed by malaria (£44.5 million;
16.8%), neglected tropical diseases (NTDs; £41.0 million; 15.5%),
tuberculosis (£20.0 million; 7.6%) and gastrointestinal infections
(£14.3 million; 5.4%).
Analysis of funding along the research and development (R&D)
value chain showed that operational research (£109.1 million;
41.3%), including epidemiological studies, was the major focus of
funding, followed by clinical trials (£74.8million; 28.3%), preclinical
research (£60.0 million; 22.7%) and product development (£20.6
million; 7.8%). In terms of tools to tackle the burden of infectious
diseases in low- and middle-income countries, vaccine research
received £12.4 million, diagnostics £2.9 million and therapeutics
£87.2 million (primarily for testing HIV antiretroviral regimens).
Analysis by funding organisation showed that the Wellcome
Trust was the largest funder by size of investment (£120.4
million; 45.6%), followed by the Department for International
Development (£77.2 million; 29.2%) and the Medical Research
Council (£54.1 million; 20.5%).
Discussion
The findings suggest that UK funding for infectious disease re-
search mirrors colonial ties, with most of the funding awarded
during the period from1997-2010 going to countries with colonial
ties to the UK. Earlier studies have demonstrated funding for dis-
eases such asmalaria following a similar pattern, with investment
reflecting colonial ties rather than disease burden.5
Although prior colonial links and current collaborations
through institutions such as the Commonwealth are important
in establishing and maintaining collaborative links, it may be
counter-productive to be allocating research funding to the coun-
tries where these links exist. Instead, research funding should be
targeted to address the disease burden and be awarded on the
basis of scientific excellence and implementation capability.
Further work is needed to assess the extent to which these links
are maintained in an effort to make reparation for past social
and economic policies, which may have contributed greatly to
the current local burden of disease, and is beyond the scope of
this paper.
Investment of research funding is vitally important in addres-
sing the disease burden worldwide and in fostering a greater
sense of global solidarity, partnership and innovation. Unbalanced
investment that directs resources primarily to countries with colo-
nial ties, and thosewhere wide use of the English languagemakes
for ease of working and facilitates the maintenance of existing
links, will neglect populations in great need elsewhere, and
must be questioned on ethical and moral grounds.
Funding organisations and countries investing in health re-
search should review their funding policies and assist countries
without colonial ties or where English is not the official language
Figure 1. Top 15 countries by total investment in infectious disease
research by UK funders 1997–2010. Dark grey: country gained its
independence from the British Empire; pale grey: country never a formal
territory of the European colonial empires.
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to combat the diseases they suffer and thus appropriately address
the global disease burden.
Supplementary data
Supplementary data are available at Transactions Online (http://
inthealth.oxford journals.org/).
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